63 related articles for article (PubMed ID: 21914507)
1. Impact of measures to enhance the value of observational surveys in rare diseases: the Fabry Outcome Survey (FOS).
Clarke JT; Giugliani R; Sunder-Plassmann G; Elliott PM; Pintos-Morell G; Hernberg-Ståhl E; Malmenäs M; Beck M;
Value Health; 2011; 14(6):862-6. PubMed ID: 21914507
[TBL] [Abstract][Full Text] [Related]
2. [Fabry disease: demographic data since introduction of enzyme replacement therapy].
Cybulla M; Walter K; Neumann HP; Widmer U; Schärer M; Sunder-Plassmann G; Jansen T; Rolfs A; Beck M
Dtsch Med Wochenschr; 2007 Jul; 132(28-29):1505-9. PubMed ID: 17607649
[TBL] [Abstract][Full Text] [Related]
3. Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry.
Beck M; Ramaswami U; Hernberg-Ståhl E; Hughes DA; Kampmann C; Mehta AB; Nicholls K; Niu DM; Pintos-Morell G; Reisin R; West ML; Schenk J; Anagnostopoulou C; Botha J; Giugliani R
Orphanet J Rare Dis; 2022 Jun; 17(1):238. PubMed ID: 35725623
[TBL] [Abstract][Full Text] [Related]
4. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry.
Ortiz A; Cianciaruso B; Cizmarik M; Germain DP; Mignani R; Oliveira JP; Villalobos J; Vujkovac B; Waldek S; Wanner C; Warnock DG
Nephrol Dial Transplant; 2010 Mar; 25(3):769-75. PubMed ID: 19846394
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of uncontrolled hypertension in patients with Fabry disease.
Kleinert J; Dehout F; Schwarting A; de Lorenzo AG; Ricci R; Kampmann C; Beck M; Ramaswami U; Linhart A; Gal A; Houge G; Widmer U; Mehta A; Sunder-Plassmann G
Am J Hypertens; 2006 Aug; 19(8):782-7. PubMed ID: 16876675
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular events in patients with fabry disease natural history data from the fabry registry.
Patel MR; Cecchi F; Cizmarik M; Kantola I; Linhart A; Nicholls K; Strotmann J; Tallaj J; Tran TC; West ML; Beitner-Johnson D; Abiose A
J Am Coll Cardiol; 2011 Mar; 57(9):1093-9. PubMed ID: 21349401
[TBL] [Abstract][Full Text] [Related]
7. Pediatric Fabry disease.
Ries M; Gupta S; Moore DF; Sachdev V; Quirk JM; Murray GJ; Rosing DR; Robinson C; Schaefer E; Gal A; Dambrosia JM; Garman SC; Brady RO; Schiffmann R
Pediatrics; 2005 Mar; 115(3):e344-55. PubMed ID: 15713906
[TBL] [Abstract][Full Text] [Related]
8. Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry.
Politei JM; Cabrera G; Amartino H; Valdez R; Masllorens F; Ripeau D; Antongiovanni N; Soliani A; Luna P; Cedrolla M; Fernandez S; Fainboim A
Int J Clin Pract; 2013 Jan; 67(1):66-72. PubMed ID: 23241050
[TBL] [Abstract][Full Text] [Related]
9. [Cardiological follow-up in patients with Fabry disease].
Pieruzzi F; Pieroni M; Chimenti C; Frustaci A; Sarais C; Cecchi F;
G Ital Cardiol (Rome); 2010; 11(7-8):566-72. PubMed ID: 21033333
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.
Weidemann F; Niemann M; Breunig F; Herrmann S; Beer M; Störk S; Voelker W; Ertl G; Wanner C; Strotmann J
Circulation; 2009 Feb; 119(4):524-9. PubMed ID: 19153271
[TBL] [Abstract][Full Text] [Related]
11. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.
Ortiz A; Oliveira JP; Waldek S; Warnock DG; Cianciaruso B; Wanner C;
Nephrol Dial Transplant; 2008 May; 23(5):1600-7. PubMed ID: 18175781
[TBL] [Abstract][Full Text] [Related]
12. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.
Hughes DA; Elliott PM; Shah J; Zuckerman J; Coghlan G; Brookes J; Mehta AB
Heart; 2008 Feb; 94(2):153-8. PubMed ID: 17483124
[TBL] [Abstract][Full Text] [Related]
13. Fabry disease and the skin: data from FOS, the Fabry outcome survey.
Orteu CH; Jansen T; Lidove O; Jaussaud R; Hughes DA; Pintos-Morell G; Ramaswami U; Parini R; Sunder-Plassman G; Beck M; Mehta AB;
Br J Dermatol; 2007 Aug; 157(2):331-7. PubMed ID: 17573884
[TBL] [Abstract][Full Text] [Related]
14. Fabry disease: a review of current management strategies.
Mehta A; Beck M; Eyskens F; Feliciani C; Kantola I; Ramaswami U; Rolfs A; Rivera A; Waldek S; Germain DP
QJM; 2010 Sep; 103(9):641-59. PubMed ID: 20660166
[TBL] [Abstract][Full Text] [Related]
15. Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey.
Lidove O; Ramaswami U; Jaussaud R; Barbey F; Maisonobe T; Caillaud C; Beck M; Sunder-Plassmann G; Linhart A; Mehta A;
Int J Clin Pract; 2006 Sep; 60(9):1053-9. PubMed ID: 16939546
[TBL] [Abstract][Full Text] [Related]
16. [Fabry disease in Italy: first epidemiologic and collaborative study].
Ricci R; Castorina M; Di Lillo M; Antuzzi D; Frustaci A; Parini R; Menni F; Furlan F; Burlina A; Burlina A; Catuogno S; Gabrielli O; Burattini I; Borsini W; Buchner S; Ferriozzi S; Spisni C; De Vito R; Di Rocco M; Aricò M; Pistone G; Bongiorno AM; Morrone A; Cavicchi C; Zammarchi E
Ann Ital Med Int; 2004; 19(4):269-75. PubMed ID: 15678707
[TBL] [Abstract][Full Text] [Related]
17. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of patients from a Spanish Registry of Fabry disease in two periods].
Barba Romero MÁ; Rivera Gallego A; Pintos Morell G;
Med Clin (Barc); 2012 Oct; 139(9):379-84. PubMed ID: 22266083
[TBL] [Abstract][Full Text] [Related]
19. Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey.
Mehta A; Clarke JT; Giugliani R; Elliott P; Linhart A; Beck M; Sunder-Plassmann G;
J Med Genet; 2009 Aug; 46(8):548-52. PubMed ID: 19473999
[TBL] [Abstract][Full Text] [Related]
20. Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products.
Sirrs SM; Arthus MF; Bichet DG; Rockman-Greenberg C; LeMoine K; Morel CF; Lachmann R; Lynd LD; Wasim S; West ML; Hollak C
Value Health; 2021 Feb; 24(2):268-273. PubMed ID: 33518033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
